Earendil Labs and Sanofi have agreed a strategic collaboration to apply Earendil's discovery platform to multiple autoimmune and inflammatory disease programmes. Sanofi will lead the development and worldwide commercialisation of bispecific candidates arising from the collaboration. According to the agreement Earendil Labs will receive up to $160 million in upfront and near-term payments tied to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!